"The
Report Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD)
- Identifying and Commercializing First-in-Class Innovation provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Chronic
Obstructive Pulmonary Disease (COPD)
is a progressive disorder associated with chronic inflammation of the
airways and lungs. Persistent breathing difficulties and repeated
exacerbations of COPD symptoms make the disease one of the leading
causes of morbidity and the fifth-leading cause of death in the
world. COPD is linked to cumulative exposure to risk factors,
primarily tobacco smoke, but also environmental pollutants. The COPD
marketed products landscape consists of pharmacological therapies
aimed at managing the symptoms associated with COPD, although none of
the available therapies have been shown to modify long-term disease
progression.
The current COPD pipeline
consists of 212 active products in development. Initial analysis
revealed a small presence of first-in-class products, constituting
16.5% of the pipeline. In comparison to other indications, this is
relatively low; however, there are some promising trends within COPD
product development. The Preclinical Phase of development is the most
active in terms of first-in-class products. This diminishes
throughout clinical development, with only two such products being
present in Phase III. However, if either of these products is
approved, they would represent the first, first-in-class products to
be approved for COPD since roflumilast, which was approved in 2011 by
the FDA and in 2010 in the EU. Roflumilast was the first novel
therapy for COPD in almost 20 years, which demonstrates the
infrequency at which first-in-class products enter the COPD market.
So to have two first-in-class products in Phase III and six in Phase
II is a promising sign.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/536325
Scope
The
COPD market has benefited from notable additions in recent years.
- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to market?
- How do the leading marketed therapies compare clinically?
The
pipeline contains a range of molecule types and molecular targets,
including those that are well established in COPD and novel,
first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- To what degree is the pipeline penetrated by first-in-class innovation?
- Which target families consist of the most first-in-class products?
Table
of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Unmet Needs Remain in COPD
Market 4
2.2 First-in-Class Innovation
Beginning to Emerge in COPD 4
2.3 COPD Lags Behind Asthma in
First-in-Class Innovation 4
3 The Case for Innovation in
COPD 5
3.1 Growing Number of
Opportunities for Biologic Products 6
3.2 Diversification of
Molecular Targets 6
3.3 Innovative First-in-Class
Product Developments Remain Attractive 6
3.4 Regulatory and
Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report
Guidance 8
4 Clinical and Commercial
Landscape 9
4.1 Disease Overview 9
4.1.1 Epidemiology 9
4.1.2 Symptoms 9
4.1.3 Etiology 9
4.1.4 Pathophysiology 9
4.1.5 Diagnosis 11
4.1.6 Assessment of Disease
Severity 11
4.1.7 Treatment 12
4.1.8 Treatment Algorithm 14
4.2 Overview of Marketed
Products 14
4.2.1 Molecule Type and Target
Analysis 15
4.2.2 Quick Relief Medication
15
4.2.3 Bronchodilator and
Inhaled Corticosteroid Combination Therapy 15
4.2.4 Bronchodilator
Monotherapy 16
4.2.5 Bronchodilator
Combination Therapy 17
4.2.6 Alternative Therapy 17
4.2.7 Conclusion 17
4.2.8 Unmet Needs 18
5 Assessment of Pipeline
Product Innovation 19
5.1 Molecular Target Analysis
21
5.2 Comparative Distribution of
Programs between COPD Market and Pipeline by Therapeutic Target
Family 26
5.3 First-In-Class Pipeline
Programs Targeting Novel Molecular Targets 26
6 Signaling Pathways, Disease
Causation and Innovation Alignment 30
6.1 The Complexity of Signaling
Networks in COPD 30
6.2 Signaling Pathways and
First-in-Class Molecular Target Integration 30
6.3 First-in-Class Target
Matrix Assessment 31
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment